Search Results - "Shiose, Yoshinobu"

A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization by Hashimoto, Yuuri, Koyama, Kumiko, Kamai, Yasuki, Hirotani, Kenji, Ogitani, Yusuke, Zembutsu, Akiko, Abe, Manabu, Kaneda, Yuki, Maeda, Naoyuki, Shiose, Yoshinobu, Iguchi, Takuma, Ishizaka, Tomomichi, Karibe, Tsuyoshi, Hayakawa, Ichiro, Morita, Koji, Nakada, Takashi, Nomura, Taisei, Wakita, Kenichi, Kagari, Takashi, Abe, Yuki, Murakami, Masato, Ueno, Suguru, Agatsuma, Toshinori

“…HER3 is a compelling target for cancer treatment; however, no HER3-targeted therapy is currently clinically available. Here, we produced U3-1402, an anti-HER3…”
Get full text

Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression by Koyama, Kumiko, Ishikawa, Hirokazu, Abe, Manabu, Shiose, Yoshinobu, Ueno, Suguru, Qiu, Yang, Nakamaru, Kenji, Murakami, Masato

“…ErbB3 (HER3), a member of the HER family, is overexpressed in various cancers and plays an important role in cell proliferation and survival. Certain HER3…”
Get full text

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd by Haikala, Heidi M, Lopez, Timothy, Köhler, Jens, Eser, Pinar O, Xu, Man, Zeng, Qing, Teceno, Tyler J, Ngo, Kenneth, Zhao, Yutong, Ivanova, Elena V, Bertram, Arrien A, Leeper, Brittaney A, Chambers, Emily S, Adeni, Anika E, Taus, Luke J, Kuraguchi, Mari, Kirschmeier, Paul T, Yu, Channing, Shiose, Yoshinobu, Kamai, Yasuki, Qiu, Yang, Paweletz, Cloud P, Gokhale, Prafulla C, Jänne, Pasi A

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are the standard-of-care treatment for -mutant non-small cell lung cancers (NSCLC)…”
Get full text

Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423 by Kashiyama, Tomoko, Oda, Katsutoshi, Ikeda, Yuji, Shiose, Yoshinobu, Hirota, Yasuhide, Inaba, Kanako, Makii, Chinami, Kurikawa, Reiko, Miyasaka, Aki, Koso, Takahiro, Fukuda, Tomohiko, Tanikawa, Michihiro, Shoji, Keiko, Sone, Kenbun, Arimoto, Takahide, Wada-Hiraike, Osamu, Kawana, Kei, Nakagawa, Shunsuke, Matsuda, Koichi, McCormick, Frank, Aburatani, Hiroyuki, Yano, Tetsu, Osuga, Yutaka, Fujii, Tomoyuki

“…DS-7423, a novel, small-molecule dual inhibitor of phosphatidylinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), is currently in phase I…”
Get full text

Current development status and prospect of dual PI3K/mTOR inhibitors for cancer therapy by Shiose, Yoshinobu

Get more information

Relationship between Drug Release of DE-310, Macromolecular Prodrug of DX-8951f, and Cathepsins Activity in Several Tumors by Shiose, Yoshinobu, Ochi, Yusuke, Kuga, Hiroshi, Yamashita, Fumiyoshi, Hashida, Mitsuru

“…DE-310 is composed of the topoisomerase-I inhibitor DX-8951 (exatecan) and carboxymethyldextran polyalcohol (CM-Dex-PA) carrier, which are covalently linked…”
Get full text

Systematic Research of Peptide Spacers Controlling Drug Release from Macromolecular Prodrug System, Carboxymethyldextran Polyalcohol−Peptide−Drug Conjugates by Shiose, Yoshinobu, Kuga, Hiroshi, Ohki, Hitoshi, Ikeda, Masahiro, Yamashita, Fumiyoshi, Hashida, Mitsuru

“…The primary purpose of this study was to comprehensively delineate specificity of the peptide spacer sequence to tumor-expressed proteases for the design of…”
Get full text

Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f by Shiose, Yoshinobu, Kuga, Hiroshi, Yamashita, Fumiyoshi, Hashida, Mitsuru

“…DE-310 is a novel macromolecular prodrug of the topoisomerase-I inhibitor DX-8951. DX-8951 is covalently linked to carboxymethyl dextran polyalcohol…”
Get full text

A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951 by OCHI, Yusuke, SHIOSE, Yoshinobu, KUGA, Hiroshi, KUMAZAWA, Eiji

“…DE-310, a new macromolecular prodrug, was designed to enhance the pharmacological profiles of a novel camptothecin analog (DX-8951f), and a single treatment…”
Get full text

Patritumab deruxtecan by Koyama, Kumiko, Ishikawa, Hirokazu, Abe, Manabu, Shiose, Yoshinobu, Ueno, Suguru, Qiu, Yang, Nakamaru, Kenji, Murakami, Masato

“…ErbB3 (HER3), a member of the HER family, is overexpressed in various cancers and plays an important role in cell proliferation and survival. Certain HER3…”
Get full text

Abstract 5201: U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits in vitro antitumor activity against breast cancer cells expressing HER3 mutations without dependence on HER2 overexpression by Koyama, Kumiko, Ishikawa, Hirokazu, Abe, Manabu, Shiose, Yoshinobu, Ueno, Suguru, Nakamaru, Kenji, Murakami, Masato

“…Abstract Background: U3-1402, a novel HER3-targeting antibody-drug conjugate (ADC) composed of a fully human anti-HER3 antibody (patritumab),…”
Get full text

Small Molecule Agonists of PPAR-γ Exert Therapeutic Effects in Esophageal Cancer by SAWAYAMA, Hiroshi, ISHIMOTO, Takatsugu, MORITA, Masaru, SHIOSE, Yoshinobu, BABA, Hideo, WATANABE, Masayuki, YOSHIDA, Naoya, SUGIHARA, Hidetaka, KURASHIGE, Junji, HIRASHIMA, Kotaro, IWATSUKI, Masaaki, BABA, Yoshifumi, OKI, Eiji

“…The transcription factor PPAR-γ plays various roles in lipid metabolism, inflammation, cellular differentiation, and apoptosis. PPAR-γ agonists used to treat…”
Get full text

Abstract 5192: EGFR inhibition enhances the cellular uptake and antitumor activity of the novel HER3 antibody drug conjugate U3-1402 by Haikala, Heidi M., Köhler, Jens, Lopez, Timothy, Eser, Pinar, Xu, Man, Yu, Channing, Shiose, Yoshinobu, Qiu, Yang, Gokhale, Prafulla, Jänne, Pasi A.

“…Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have changed the treatment landscape for EGFR-mutant non-small cell lung…”
Get full text

Abstract 5880: Pan-cancer gene expression analysis of tissue microarray using EdgeSeq Oncology Biomarker Panel and a cross-comparison with ERBB3 immunohistochemical analysis by Inaki, Koichiro, Maeda, Naoyuki, Shibutani, Tomoko, Eppenberger-Castori, Serenella, Nicolet, Stefan, Koyama, Kumiko, Tanaka, Yui, Kaneda, Yuki, Wakita, Kenichi, Shiose, Yoshinobu, Murakami, Masato

“…Abstract Background: Antibody-drug conjugate (ADC) is one of the recent break-through approaches of targeting tumors, in which chemotherapeutic agents are…”
Get full text

Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression by Kumiko Koyama, Hirokazu Ishikawa, Manabu Abe, Yoshinobu Shiose, Suguru Ueno, Yang Qiu, Kenji Nakamaru, Masato Murakami

“…ErbB3 (HER3), a member of the HER family, is overexpressed in various cancers and plays an important role in cell proliferation and survival. Certain HER3…”
Get full text

Abstract LB-275: U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits its antitumor activity through increased payload intracellular delivery via highly efficient drug internalization by Koyama, Kumiko, Hashimoto, Yuuri, Kamai, Yasuki, Shiose, Yoshinobu, Abe, Manabu, Kaneda, Yuki, Maeda, Naoyuki, Hirotani, Kenji, Ogitani, Yusuke, Karibe, Tsuyoshi, Kagari, Takashi, Wakita, Kenichi, Ueno, Suguru, Agatsuma, Toshinori, Murakami, Masato

“…Abstract Background: Human epidermal growth factor receptor 3 (HER3), a member of the ErbB receptor tyrosine kinase family, is overexpressed in a variety of…”
Get full text

Synthesis and evaluation of novel orally active p53–MDM2 interaction inhibitors by Miyazaki, Masaki, Naito, Hiroyuki, Sugimoto, Yuuichi, Yoshida, Keisuke, Kawato, Haruko, Okayama, Tooru, Shimizu, Hironari, Miyazaki, Masaya, Kitagawa, Mayumi, Seki, Takahiko, Fukutake, Setsuko, Shiose, Yoshinobu, Aonuma, Masashi, Soga, Tsunehiko

“…We have discovered and reported potent p53–MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold. Our lead showed strong activity in vitro,…”
Get full text

Abstract 6579: DS-3939a, a novel TA-MUC1-targeting antibody-drug conjugate (ADC) with a DNA topoisomerase I inhibitor DXd, exhibits potent antitumor activity in preclinical models by Yukiura, Mayuko, Takano, Kohei, Takahashi, Kazuki, Zembutsu, Akiko, Kitamura, Michiko, Shiose, Yoshinobu, Honda, Kokichi, Oyama, Kazunori, Obuchi, Wataru, Yamada, Makiko, Goto, Riki, Sakurai, Ken, Kumagai, Kazuyoshi, Kagari, Takashi, Abe, Yuki, Agatsuma, Toshinori

“…Abstract Background: Tumor-associated mucin-1 (TA-MUC1) is a tumor-specific transmembrane glycoprotein with aberrant glycosylation. It is highly expressed in…”
Get full text

Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma by Koul, Dimpy, Wang, Shuzhen, Wu, Shaofang, Saito, Norihiko, Zheng, Siyuan, Gao, Feng, Kaul, Isha, Setoguchi, Masaki, Nakayama, Kiyoshi, Koyama, Kumiko, Shiose, Yoshinobu, Sulman, Erik P, Hirota, Yasuhide, Yung, W K Alfred

“…Glioblastoma (GBM) is an ideal candidate disease for signal transduction targeted therapy because the majority of these tumors harbor genetic alterations that…”
Get full text

ATPS-46PRECLINICAL THERAPEUTIC EFFICACY OF A NOVEL BLOOD-BRAIN BARRIER-PENETRANT DUAL PI3K/MTOR INHIBITOR WITH PREFERENTIAL RESPONSE IN PI3K/PTEN MUTANT GLIOMA by Koul, Dimpy, Wang, Shuzhen, Saito, Norihiko, Zheng, Siyuan, Wu, Shaofang, Setoguchi, Masaki, Nakayama, Kiyoshi, Koyama, Kumiko, Shiose, Yoshinobu, Sulman, Erik P., Hirota, Yasuhide, Yung, W. K. Alfred

Get full text